LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Al-Hattab, Eyad"
  2. AU="Hou, Tsung-Wei"
  3. AU="Meng, Ying Shirley"
  4. AU="Emanuele Rezoagli"
  5. AU="Verhagen, M A M T"
  6. AU="Haden, Kathleen"
  7. AU="Lee, Ju Yup"
  8. AU="Camilla Caimi"
  9. AU="Huynh, Nancy"
  10. AU="Sun, Weilin"
  11. AU="Whalon, Mark E."
  12. AU=Grishunin Kirill
  13. AU="Quaranta, Gianluigi"
  14. AU="Jitaroon, Kawinyarat"
  15. AU="Anderson, Eric C"
  16. AU="Thiyagarajan, Kamalraj"
  17. AU="Simnica, Donjetë"

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel ; Online: Patient Understanding of Chemotherapy and Goals of Care as Provided by Different Care Team Members.

    Suhail, Shanzay / Basu, Sandeep / Batoo, Sameer A / Al-Hattab, Eyad S / Kanj Ahmed, Ola / Eidahl, Barbara J / Okuno, Scott H

    Journal of cancer education : the official journal of the American Association for Cancer Education

    2023  Band 38, Heft 4, Seite(n) 1215–1223

    Abstract: Chemotherapy can be challenging and overwhelming for patients, but when patients are knowledgeable about chemotherapy, their comfort level, overall satisfaction, and coping improve. It is currently unknown whether patients prefer information about ... ...

    Abstract Chemotherapy can be challenging and overwhelming for patients, but when patients are knowledgeable about chemotherapy, their comfort level, overall satisfaction, and coping improve. It is currently unknown whether patients prefer information about chemotherapy to be provided by specific care team members and whether demographic characteristics affect learning preferences. We developed a 31-question questionnaire that asked patients when chemotherapy information was discussed and who they wanted that information to come from. The questionnaire was given to 50 patients who had completed 1 cycle of chemotherapy. Patients were evenly distributed among age categories of 45 to 64 years, 65 to 74 years, and 75 years or older. Thirty participants (60%) were women, 33 (66%) had high school degrees, and 23 (46%) were receiving their first chemotherapy regimen. Sixty percent of patients best understood goals of care from oncologists, 70% wanted goals of care to come from oncologists, and 61% best understood and wanted to understand logistics of chemotherapy from oncologists. Sixty-six percent of patients understood adverse effects when they were explained by nursing staff, and 56% wanted explanations of adverse effects to come from nursing staff. Patients did not prefer a specific care team member or information source when receiving financial cost information. Patients often preferred to receive chemotherapy information from their oncologist; however, other members of the care team also provided information to patients in a way that was understood.
    Mesh-Begriff(e) Humans ; Female ; Middle Aged ; Male ; Patients ; Surveys and Questionnaires ; Drug-Related Side Effects and Adverse Reactions ; Patient Care Planning ; Patient Care Team
    Sprache Englisch
    Erscheinungsdatum 2023-01-03
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632898-2
    ISSN 1543-0154 ; 0885-8195 ; 1543-1154
    ISSN (online) 1543-0154
    ISSN 0885-8195 ; 1543-1154
    DOI 10.1007/s13187-022-02251-y
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2185: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.

    Bayraktar, Soley / Batoo, Sameer / Al-Hattab, Eyad / Basu, Sandeep / Okuno, Scott / Glück, Stefan

    Future oncology (London, England)

    2020  Band 16, Heft 32, Seite(n) 2661–2672

    Abstract: There are three US FDA-approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choose ... ...

    Abstract There are three US FDA-approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choose among these agents and how to sequence them. Other areas with active investigation include identifying predictive biomarkers for the selection of patients whom may benefit more from CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression on CDK4/6 inhibitors, creating novel treatment combinations and expanding use beyond HR+/HER2- MBC. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+/HER2- MBC.
    Mesh-Begriff(e) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/drug therapy ; Breast Neoplasms/etiology ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Female ; Humans ; Molecular Targeted Therapy ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Treatment Outcome
    Chemische Substanzen Biomarkers, Tumor ; Protein Kinase Inhibitors ; Receptors, Estrogen ; Receptors, Progesterone ; CDK4 protein, human (EC 2.7.11.22) ; CDK6 protein, human (EC 2.7.11.22) ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22)
    Sprache Englisch
    Erscheinungsdatum 2020-08-17
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2020-0234
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6478: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Bortezomib and daratumumab in refractory autoimmune hemolytic anemia.

    McGlothlin, John / Abeykoon, Jithma / Al-Hattab, Eyad / Ashrani, Aneel A / Elliott, Michelle / Hook, C Christopher / Pardanani, Animesh / Pruthi, Rajiv / Sridharan, Meera / Wolanskyj, Alexandra / Rouse, Rachelle / Go, Ronald

    American journal of hematology

    2023  Band 98, Heft 10, Seite(n) E263–E265

    Mesh-Begriff(e) Humans ; Bortezomib/therapeutic use ; Anemia, Hemolytic, Autoimmune/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Dexamethasone
    Chemische Substanzen Bortezomib (69G8BD63PP) ; daratumumab (4Z63YK6E0E) ; Antibodies, Monoclonal ; Dexamethasone (7S5I7G3JQL)
    Sprache Englisch
    Erscheinungsdatum 2023-07-07
    Erscheinungsland United States
    Dokumenttyp Letter
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27025
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1251: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

    Batoo, Sameer / Bayraktar, Soley / Al-Hattab, Eyad / Basu, Sandeep / Okuno, Scott / Glück, Stefan

    Journal of carcinogenesis

    2019  Band 18, Seite(n) 5

    Abstract: With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor ... ...

    Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. Then, pertuzumab in 2012 and ado-trastuzumab emtansine in 2013 were approved in the US and elsewhere based on evidence showing an improvement in survival outcomes in patients with mostly trastuzumab naïve or trastuzumab-exposed metastatic disease. The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors.
    Sprache Englisch
    Erscheinungsdatum 2019-12-31
    Erscheinungsland India
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2098237-9
    ISSN 1477-3163 ; 1477-3163 ; 0974-6773
    ISSN (online) 1477-3163
    ISSN 1477-3163 ; 0974-6773
    DOI 10.4103/jcar.JCar_14_19
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.

    Westerhout, Cynthia M / Fu, Yuling / Lauer, Michael S / James, Stefan / Armstrong, Paul W / Al-Hattab, Eyad / Califf, Robert M / Simoons, Maarten L / Wallentin, Lars / Boersma, Eric

    Journal of the American College of Cardiology

    2006  Band 48, Heft 5, Seite(n) 939–947

    Abstract: Objectives: The purpose of this study was to develop 30-day and 1-year risk stratification models for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate quantitative ST-segment depression and novel biomarkers.: ... ...

    Abstract Objectives: The purpose of this study was to develop 30-day and 1-year risk stratification models for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate quantitative ST-segment depression and novel biomarkers.
    Background: Several novel biomarkers have changed the risk profile of ACS; thus, the reassessment of traditional indicators such as ST-segment depression in this new context is warranted.
    Methods: Multivariable logistic regression was used to identify significant predictors of 30-day death and death/myocardial infarction (MI) and 1-year mortality in 7,800 NSTE-ACS patients enrolled in the GUSTO-IV (Global Utilization of Strategies to Open Occluded Arteries-IV ACS) trial between 1998 and 2000.
    Results: Among all other predictors, the degree of ST-segment depression had the highest prognostic value for 30-day death, 30-day death/MI, and 1-year death. Troponin T (TnT), creatinine clearance, N-terminal pro-brain natriuretic peptide (NT-proBNP), heart rate, and age were also highly influential on adverse outcomes. Unlike TnT and NT-proBNP, C-reactive protein was only predictive of long-term death. In contrast to mortality, the contribution of TnT to predicting 30-day death/MI increased, whereas NT-proBNP's role was attenuated. The discriminatory power was excellent (c-index [adjusted for over-optimism]: 0.82 [30-day death]; 0.72 [30-day death/MI]; 0.81 [1-year]).
    Conclusions: In this large contemporary study of NSTE-ACS patients, novel insights into risk stratification were observed-in particular, the utility of quantitative ST-segment depression and multiple biomarkers. Collection of these indicators in future NSTE-ACS populations is recommended to evaluate generalizability and clinical application of these findings.
    Mesh-Begriff(e) Aged ; Biomarkers/analysis ; C-Reactive Protein/analysis ; Creatinine/metabolism ; Electrocardiography ; Female ; Humans ; Logistic Models ; Male ; Middle Aged ; Myocardial Infarction/etiology ; Myocardial Infarction/mortality ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Predictive Value of Tests ; Prognosis ; Risk Assessment ; Survival Analysis ; Troponin T/blood
    Chemische Substanzen Biomarkers ; Peptide Fragments ; Troponin T ; pro-brain natriuretic peptide (1-76) ; Natriuretic Peptide, Brain (114471-18-0) ; C-Reactive Protein (9007-41-4) ; Creatinine (AYI8EX34EU)
    Sprache Englisch
    Erscheinungsdatum 2006-09-05
    Erscheinungsland United States
    Dokumenttyp Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2006.04.085
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1846: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 196: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang